Incyte's (INCY) Jakafi Granted FDA Orphan Drug Designation in Graft Versus Host Disease

November 4, 2016 9:09 AM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Incyte (NASDAQ: INCY) Jakafi was granted FDA orphan drug designation in Graft Versus Host Disease.

Generic Name: ruxolitinib
Trade Name: Jakafi
Date Designated: 11/03/2016
Orphan Designation: Treatment of graft versus host disease
Orphan Designation Status: Designated
FDA Orphan Approval Status:Not FDA Approved for Orphan Indication
Marketing Approval Date: N/A
Approved Labeled Indication:
Exclusivity End Date: N/A
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, Delaware 19803
USA

The sponsor address listed is the last reported by the sponsor to OOPD.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA

Add Your Comment